K. Mulvaney

发表

Discovery of a first-in-class inhibitor of the PRMT5-substrate adaptor interaction

W. Sellers, D. Porter, P. McCarren, 2021, bioRxiv.

Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.

W. Sellers, M. Drysdale, D. Porter, 2021, Journal of medicinal chemistry.

Molecular basis for substrate recruitment to the PRMT5 methylosome

W. Sellers, D. Porter, D. Raymond, 2020, bioRxiv.

Protein arginine methyltransferase 5 (PRMT5) is a Type II arginine methyltransferase and an essential enzyme. PRMT5 symmetrically dimethylates substrate proteins by catalyzing the 2-step transfer of 2 methyl groups from 2 S-adenosyl methionine (SAM) co-factor molecules to specific arginine residues

W. Sellers, Brian J McMillan, D. Raymond, 2020 .

Loss of SWI/SNF Chromatin Remodeling Alters NRF2 Signaling in Non–Small Cell Lung Carcinoma

D. Hayes, V. Walter, B. Weissman, 2020, Molecular Cancer Research.

Identification and Characterization of MCM3 as a Kelch-like ECH-associated Protein 1 (KEAP1) Substrate*

J. Cook, D. Goldfarb, C. Vaziri, 2016, The Journal of Biological Chemistry.

Molecular and Cellular Pathobiology Proteomic Analysis of Ubiquitin Ligase KEAP 1 Reveals Associated Proteins That Inhibit NRF 2 Ubiquitination

Bridgid E Hast, D. Hayes, D. Goldfarb, 2013 .

Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination.

Bridgid E Hast, D. Hayes, D. Goldfarb, 2013, Cancer research.

Coordinate loss of MHC class II expression in the diffuse large B cell lymphoma cell line OCI-Ly2 is due to a novel mutation in RFX-AP

Kelly A. Cycon, K. Mulvaney, M. Bushway, 2010, Immunogenetics.

Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B‐cell lymphoma

L. Rimsza, D. Persky, Kelly A. Cycon, 2013, Immunology.

Dissecting the Keap1/Nrf2 pathway through proteomics

M. B. Major, Tigist Y. Tamir, K. Mulvaney, 2016 .

Engineering a genetically encoded competitive inhibitor of the KEAP1-NRF2 interaction via structure-based design and phage display.

Steven M. Lewis, B. Kuhlman, Gurkan Guntas, 2015, Protein engineering, design & selection : PEDS.

PROTEOMIC DISSECTION OF KEAP1/NRF2 SIGNALING TO DETERMINE NEW PATHWAY INTERACTORS IN CANCER

K. Mulvaney, 2015 .

A conditional mouse expressing an activating mutation in NRF2 displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissue

D. Hayes, J. Simon, B. Weissman, 2020, The Journal of pathology.

Molecular basis for substrate recruitment to the PRMT5 methylosome.

W. Sellers, D. Porter, A. Aguirre, 2021, Molecular cell.